RxDoctor Payments Data

Sareen Barbouletos, MD

Internal Medicine · Woodbury Heights, NJNPI 1841464054

Payments from drug & device makers

$487in general payments, 2019–2025

Across 20 payments — averaging $24.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$163
  • Pfizer$146
  • GSK$45
  • AstraZeneca$29
  • Johnson & Johnson$19
  • Amgen$18
  • plus $67 from 5 others

What the payments were for

  • Food & beverage$487100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$487 in reported general payments places this provider in the 55th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$145,363
Medicare patients
408
Services billed
3,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin62$71,011
OzempicSemaglutide36$53,764
EliquisApixaban47$39,481
TrulicityDulaglutide30$39,383
JanuviaSitagliptin Phosphate26$37,043
MounjaroTirzepatide28$32,903
XareltoRivaroxaban13$18,626
FarxigaDapagliflozin Propanediol11$17,589
MyrbetriqMirabegron22$17,465
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$8,962
Valsartan183$7,895
Rosuvastatin Calcium402$6,980
Atorvastatin Calcium512$5,908
Levothyroxine Sodium307$4,152
SynthroidLevothyroxine Sodium49$4,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$14$72,28758 claims
Boehringer IngelheimJardiance$14$71,01162 claims
Novo NordiskOzempic$163$53,76436 claims
PfizerEliquis$146$39,48147 claims
MerckJanuvia$12$37,04326 claims
Johnson & JohnsonXarelto$19$18,62613 claims
AstraZenecaFarxiga$29$17,58911 claims
GSKAnoro Ellipta$45$8,96214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Woodbury Heights

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →